Immunotherapy in Melanoma | Specialty

Hedgehog Pathway Remains a Ripe Target in Many Malignancies

October 21st 2015

The Hedgehog pathway is one of several key developmental cell-signaling networks whose aberrant activation in adult tissues can lead to cancer.

Dr. Patricia LoRusso on Next-Generation Sequencing Benefit in Metastatic Melanoma Treatment

October 16th 2015

Patricia M. LoRusso, DO, Professor of Medicine and Associate Director of Innovative Medicine, Yale Cancer Center, discusses taking a personalized medicine approach to treat melanoma patients whose tumors do not have BRAF alterations.

Three FDA Approvals and Two Priority Reviews

October 9th 2015

Cobimetinib/Vemurafenib Combo Improves Survival in Melanoma

October 6th 2015

The combination of vemurafenib and cobimetinib demonstrated a statistically significant improvement in overall survival compared with vemurafenib alone for previously untreated patients with BRAFV600-mutant unresectable or metastatic melanoma.

FDA Approves Nivolumab/Ipilimumab Combination for BRAF Wild-Type Melanoma

October 1st 2015

The FDA has granted an accelerated approval to the combination of nivolumab and ipilimumab as a treatment for patients with BRAF V600 wild-type unresectable or metastatic melanoma.

Dabrafenib/Trametinib Combo Improves OS Versus Vemurafenib in Advanced Melanoma

September 27th 2015

The combination of dabrafenib plus trametinib improved overall survival by 7.6 months compared with single-agent vemurafenib in patients with unresectable or metastatic BRAFV600E/K-mutant melanoma.

T-VEC/Pembrolizumab Combination Demonstrates Safety in Melanoma

September 27th 2015

The combination of the attenuated oncolytic virus talimogene laherparepvec and the immune checkpoint inhibitor pembrolizumab for unresectable melanoma has passed an early safety evaluation.

Nivolumab Before Ipilimumab Has Greater Efficacy, Similar AEs

September 27th 2015

Two strategies of sequential immunotherapy for advanced melanoma showed similar safety and tolerability but substantially different efficacy.

FDA Grants Nivolumab/Ipilimumab Combination Priority Review for Advanced Melanoma

September 26th 2015

The FDA has granted a priority review designation to a supplemental biologics license application for nivolumab plus ipilimumab in previously untreated patients with advanced melanoma.

Jeffrey Weber Joins NYU Langone, Plans to Expand Clinical Trial and Immunotherapy Initiatives

September 25th 2015

Immunotherapy expert Jeffrey Weber, MD, PhD, will join NYU Langone Medical Center's Laura and Isaac Perlmutter Cancer Center as its deputy director and co-director of its melanoma program.

Dr. Luke Discusses Combination Approaches on Horizon in Melanoma

September 17th 2015

Jason J. Luke, MD, assistant professor of Medicine, University of Chicago Medicine, discusses combination approaches that are on the horizon for the treatment of patients with melanoma.

Advanced Squamous Carcinoma of the Skin: A Persistent, Growing Challenge

September 12th 2015

Advanced SCCS continues to be a treatment challenge given the aggressive behavior of a subset of cases and the absence of randomized clinical trials to provide guidelines for therapy.

Dr. Grilley-Olson on Treating Patients Based on Molecular Profile

September 8th 2015

Juneko Grilley-Olson, MD, assistant professor, UNC-Chapel Hill, Clinical Research, Thoracic Oncology Program, Head and Neck Oncology Program, Bone and Soft Tissue Oncology Program, UNC Lineberger Comprehensive Cancer Center, discusses treating patients with cancer based on their molecular profile.

Dr. Piccioni on Tumor Profiles of Brain Metastases

September 2nd 2015

David Piccioni, MD, PhD, assistant professor, Neuroscience and Neuro-Oncology, UC San Diego Health, discusses tumor profiling of brain metastases of patients with non-small cell lung cancer, breast cancer, and melanoma.

Dabrafenib/Trametinib Combo Granted EU Approval for Advanced Melanoma

September 1st 2015

The combination of dabrafenib (Tafinlar) plus trametinib (Mekinist) has been approved in the EU for advanced melanoma.

Combination Therapies Continue to Advance in Melanoma

August 31st 2015

Anna Pavlick, DO, discusses immunotherapy and targeted combination regimens in advanced melanoma.

Eltrombopag Approval, Cabozantinib Breakthrough Designation, Pembrolizumab Priority Review, and More

August 28th 2015

Sonidegib Approved in Europe for Basal Cell Carcinoma

August 20th 2015

The European Commission has approved the hedgehog inhibitor sonidegib (Odomzo) for the treatment of patients with locally advanced basal cell carcinoma (laBCC) who are not amenable to curative surgery or radiation therapy.

Frontline Pembrolizumab Receives FDA Priority Review in Melanoma

August 18th 2015

The FDA has granted a priority review to pembrolizumab (Keytruda) as a frontline treatment for patients with advanced melanoma.

FDA Delays Decision on Frontline Nivolumab in Melanoma

August 12th 2015

The FDA has extended the review period for frontline nivolumab in patients with advanced melanoma by 3 months, to allow ample time to review additional data submitted by the PD-1 inhibitor's developer Bristol-Myers Squibb.